Recent estimates on two spinal muscular atrophy (SMA) therapies could fuel already-heated debates over the prices of new drugs when they hit the market, STAT reports.
The Institute for Clinical and Economic Review (ICER) recently suggested significant price reductions to the two drugs, Biogen’s Spinraza and Novartis’ Zolgensma.
Spinraza was approved in 2016, though Zolgensma still awaits a decision by the Food and Drug Administration.
To read the full report on STAT, click here. (Paid subscription required)